Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Container type matters
A higher proportion of patients treated with tirzepatide achieved weight loss of 5% or greater (96% vs approximately 86%), 10% or greater (90% vs ~69%), and 15% or greater (78% vs ~50%)
Stability & Half-Life Data CJC-1295 (Modified GRF 1-29) plasma half-life: Approximately 30 minutes following subcutaneous administration in rodent pharmacokinetic studies
A decade of progress in type 2 diabetes and cardiovascular disease: Advances in SGLT2 inhibitors and GLP-1 receptor agonistsa comprehensive review
Results will vary by patient, intervention, and medication prescribed (if appropriate)
US$ 24.98
US$ 26.13
US$ 26.18
US$ 21.27
US$ 23.37
